BPO 0.00% 0.3¢ bioprospect limited

any good news on the options, page-14

  1. 6,187 Posts.
    lightbulb Created with Sketch. 497
    APATH update not regarded a material ie >$30,000 - so heading was a slip - no update deemed necessary to be released to market.

    Max capital to underwrite 30-6-7 options, will cost $220 [maximum] plus 1/3 again of 2010 0.05 options [$1.8M return 2010] for maximum possible purchase of conversions 97M heads. My thinking that the worse case scenario with the deal is, if MAX Cap want out in a hurry, 2-3 good days of market absorption on the back of very good news - or 2-3 month of SP bleeding if no good news. But on back of what I gleaned at GM, I happy the former will be the case and a bleed won't eventuate. So should net BPO $4.5M for upcoming works. [yep - I stole this post from myself over at $hare$cene forum]
 
watchlist Created with Sketch. Add BPO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.